Spatial Releases 2025 1.0.1 with Enhancements for CAD Translation, Model Simplification, and Mesh Preparation for Manufacturing and Simulation

BROOMFIELD, Colo., May 02, 2025--(BUSINESS WIRE)--Spatial Corp., the leading software development toolkit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, announces the 2025 1.0.1 release and updates across several product lines, reaffirming its commitment to providing innovative solutions for its customers in domains ranging from CAD to simulation, manufacturing, and beyond.
The 2025 1.0.1 release delivers expanded functionality designed to streamline manufacturing and simulation workflows. Key highlights include a new custom feature detection API in ACIS for more efficient model simplification, expanded CAD format support—including STEP AP242 PMI writing—and continued enhancements to hidden-body removal. With this release, Spatial reduces manual tasks, increases fidelity in geometry translation, and strengthens its toolset for automated design-to-manufacture and design-to-simulation pipelines.
3D ACIS Modeler
Custom Feature Detection (Beta): Model simplification often requires manual and repetitive tasks by end-users. This capability allows end-users to define a custom feature and automatically detect other instances of it in the model.
Panel Ray Fire: Instead of firing individual rays, your application can use this new interface to define an array of rays in a structured rectangular pattern, which significantly boosts performance.
Skinning Enhancements: Optimized algorithms reduce twists and self-intersections to deliver cleaner, more accurate output surfaces.
3D InterOp
Creo Reader Improvements
Cosmetic Sketch Translation: Convert text from cosmetic sketches into wireframe bodies to support engraving workflows.
Table Patterns: Table patterns are a flexible way to specify the locations of features for machining processes such as drilling, milling, cutting, or punching of holes. This release now supports the extraction of table patterns.
Sketch Support for Inventor: Import sketch data as wire bodies from Inventor 2023 and later.
STEP AP242 Support: Writing imported semantic PMI data to STEP AP242 is now supported. Authoring PMI data is expected to be available in time for the next release.
Wire support in glTF Writer: This functionality lets customers convert CAD files with PMI to glTF for web viewing applications.
Updated CAD Format Version Support:
IFC 4.3.2.0
NX 2412
Parasolid 37.0
Revit 2025
Solid Edge 2025
Data Prep – 3D InterOp Add-On
Hidden Body Removal: For parts, a new optional behavior allows hidden bodies to be identified and marked-up without being removed. Hidden body removal for assemblies is now available in a limited form for demonstration purposes. Customers may expect further improvements to hidden body removal soon as Data Prep continues to be a prime focus for Spatial.
CGM Modeler
Generate parallel curves on a body (Beta): This release introduces a new operator to create parallel curves on a body's surface, separated by a specified geodesic distance. This feature is especially beneficial in manufacturing workflows requiring precise spacing between adjacent toolpaths.
C# interface: This update implements several memory management improvements.
CSM-CVM
CVM mesh quality improvements: Mesh regularity has been improved in adaptive workflows.
CDS
Support for soft constraints: Ability to convert between geometric constraint and soft constraint.
About Spatial Corp.
Spatial Corp., a Dassault Systèmes subsidiary, is the leading provider of 3D software development toolkits for technical applications across a broad range of industries. Spatial 3D modeling, 3D visualization, and CAD translation software development toolkits help application developers deliver market-leading products, maintain focus on core competencies, and reduce time-to-market. For over 35 years, Spatial's 3D software development toolkits have been adopted by many of the world's most recognized software developers, manufacturers, research institutes, and universities. Headquartered in Broomfield, Colorado, Spatial has offices in the USA, France, Germany, Japan, China, and the United Kingdom. For more information on Spatial's latest updates and product offerings, please visit www.spatial.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250430198391/en/
Contacts
Spatial Corp. Press Contact Feriel JEDIDI DUPONT+33 1 6162 8201Feriel.JEDIDI@3ds.com

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

6 hours ago

• Yahoo

A First-Time Buyer Was Shocked When Their Escrow Shot Up. Turns Out, A Fixed Rate Doesn't Protect You From Tax And Insurance Hikes

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. When a Reddit user and their husband bought a home in 2021, they felt confident with their $1,250 monthly mortgage payment. It was a fixed-rate loan, and they had budgeted carefully. But that confidence quickly turned to confusion when their payment jumped to $1,600. At first, the couple thought their private mortgage insurance had increased. 'We've been in contact with our lender and they said the only way to get off the PMI is to get a home appraisal above $331K,' the person wrote in the r/FirstTimeHomeBuyer subreddit recently. So, her husband paid $500 for an appraisal that did meet the target value. But the lender said it was invalid because the appraiser wasn't on their approved list. They were told they'd need to pay $650 for another appraisal through the lender's channels. Don't Miss: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can Redditors were quick to point out what was really going on. 'Your PMI does not go up. Only your escrow for insurance and taxes can go up,' one top commenter said. Another added, 'Interagency appraisal guidelines prohibit financial institutions from using appraisals ordered directly by the borrower.' The original poster later confirmed what many had suspected: 'I asked our mortgage lender to send our last few escrow reports and it was in fact our hazard insurance causing the increase, not our PMI like we originally thought.' The takeaway was this: even with a fixed interest rate, escrow payments can shift drastically because of tax reassessments and insurance hikes. 'Be prepared for your escrow—property taxes and insurance—to go up even if you got a 'fixed rate' mortgage,' the OP warned. Trending: , which provides access to a pool of short-term loans backed by residential real estate with just a $100 minimum. Many commenters shared similar stories. One person said their mortgage payment rose by $800 due to an insurance lapse and property tax increase. Others explained how taxes often spike after a property changes hands, since previous owners may have had exemptions or lower assessments. 'My homeowners insurance went from $1,400 to $2,800 over a three-year span,' one person said. 'I shopped and found insurance with the same coverage for $1,300 again, only to be told they wouldn't cover the house due to them feeling the roof was old. I was forced to spend $12,000 for a new roof in 30 days.'The good news is that there are options. Homeowners can shop around for better insurance rates, dispute property tax assessments, and ask lenders for a broker price opinion instead of a full appraisal to remove PMI. 'I requested the PMI to be removed and was given two options,' one person explained. 'I went with the BPO and it was only $140. Ten days later, my PMI was removed.' Others suggested reviewing escrow statements annually and proactively paying shortages to avoid ballooning payments. 'If you pay the $1200 shortfall, you will owe $100 more a month. If you don't pay it off all at once, you will owe $200 more a month because you're paying the shortfall plus the extra $100 monthly,' one commenter warned. As for the original poster, she ended the thread with a lesson for others: 'As much as some people like to act like home buying and everything involved is intuitive and common sense, it's really not. So I hope you all can learn from our boo boo.' Read Next: Maximize saving for your retirement and cut down on taxes: . This Jeff Bezos-backed startup will allow you to .This article A First-Time Buyer Was Shocked When Their Escrow Shot Up. Turns Out, A Fixed Rate Doesn't Protect You From Tax And Insurance Hikes originally appeared on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Business Wire

11 hours ago

• Business Wire

GE HealthCare drives innovation in theranostics with latest technological advances

CHICAGO--(BUSINESS WIRE)--At this year's Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE HealthCare is spotlighting the future of precision care with its innovative portfolio of theranostics-enabling solutions designed to help drive clinical and operational excellence. Making its debut, GE HealthCare's MIM Software introduces LesionID Pro with automated zero-click pre-processing i – an AI-powered innovation to help aid physician decision making and therapy response monitoring. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief Share With cancer accounting for over 10 million deaths globally each year, ii the rise of precision care – particularly theranostics – is offering new hope to patients. By combining advanced diagnostic imaging and radiopharmaceuticals with targeted therapies, theranostics enables a personalized, patient-centric approach that may help improve disease detection, treatment accuracy, and overall quality of life. 'Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice,' shares Shyam Srinivas, MD, PhD, Chief of Nuclear Medicine, Associate Clinical Professor, Department of Radiological Sciences, University of California, Irvine. 'With tools like GE HealthCare's Omni Legend, StarGuide, and MIM software at our disposal, we now have the ability to visualize disease with great clarity, quantify tumor burden efficiently, and make fast, informed decisions. These advancements are not only helping enhance diagnostic accuracy and therapy monitoring but are also opening the door to dosimetry—ultimately helping improve outcomes for our patients. This is precision care in action, and it's making a real difference in patients' lives.' Central to the practice of theranostics is molecular imaging, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), which provides detailed, patient-specific insights to guide and monitor treatment. However, accessing these insights – like whole-body tumor burden, which represents the total amount of cancer is in the body – has traditionally required time-consuming manual analysis, resulting in clinical and operational challenges. In response, GE HealthCare's MIM Software is introducing LesionID Pro with automated zero-click pre-processing, i designed with AI-powered automation to help physicians access reliable whole-body tumor burden statistics without having to spend hours manually segmenting lesions, removing normal physiologic uptake, and registering multiple patient images for comparison. In addition to turning manual pre-processing into a zero-click experience, this new version of LesionID Pro comes with significant algorithm improvements that provide physicians with a precise whole-body tumor volume to review and finalize. Intuitive, user-friendly tools were intentionally designed with input from leading theranostics practitioners with the ultimate goal of making whole-body tumor burden analysis a practical clinical reality and help shorten physicians' time-to-report. 'At GE HealthCare, we are dedicated to providing clinicians the precision care tools needed for the adoption and practice of theranostics,' shares Jean-Luc Procaccini, President & CEO, Molecular Imaging & Computed Tomography, GE HealthCare. 'We designed our portfolio of precision care solutions to evolve with healthcare system needs and help support a patient's entire care journey – from the imaging equipment needed for a noninvasive look at a patient's anatomy and treatment monitoring, to novel radiopharmaceuticals used to diagnose and monitor disease and the systems required to produce them, to the software optimized to enable data-driven decision-making. In the hands of clinicians, these tools help advance the global practice of personalized medicine and help improve patient outcomes.' Also on display at #SNMMI25, as part of GE HealthCare's comprehensive portfolio of theranostics-enabling solutions for clinical and operational excellence, are the following innovations: MINItrace Magni, iii GE HealthCare's newest cyclotron technology, designed with a small footprint (about the size of a commercial refrigerator) and the goal of providing an easy-to-site, easy-to-install solution for the reliable, in-house production of commercial PET tracers and radiometals, including Gallium-68, used in diagnostic imaging to support personalized care plans. Adoption of such easy-to-site, easy-to-install technology may help enhance the capabilities of the healthcare system but also grant clinicians the ability to offer a variety of tracers to their patients and encourage the practice of precision care locally, helping fuel inhouse Theranostics capabilities. Omni Legend is a performance-focused PET/CT designed to evolve and help meet growing healthcare system demands by enabling clinicians to reduce dose by up to 40% iv while maintaining exceptional image quality. Supportive of the diagnostic portion of theranostics, the system continues to gain in popularity, representing the company's fastest-ever-selling PET/CT. v StarGuide is a digital SPECT/CT with a 12 CZT detector design that delivers high-quality 3D images and short scan times. Optimized for certain theranostic procedures, the system is designed to help clinicians pinpoint the size, shape, and position of lesions and monitor therapy with exceptional precision. Its flexibility in patient scanning and workflow efficiencies also support high patient throughput and help reduce complexity. For oncology patients, especially those in pain, short scans can help enhance comfort and overall experience. Aurora is an advanced dual-head SPECT/CT designed with excellent diagnostic capabilities vi and streamline workflows, offering clinicians excellent image quality and operational efficiency. Its CT has a 40 mm detector – twice the detector coverage compared to CTs of other hybrid systems vii – with the ability to reduce the dose up to 82%, viii support accurate quantitation, and help clinicians make the personalized care decisions that are at the heart of theranostics. Theranostics Pathway Manager Tile is an easy-to-use application, available on GE HealthCare's Command Center software, that is designed to simplify the time-consuming task of coordinating the theranostics care pathway. It does so by tracking patient readiness for therapy, eliminating the need for manual data gathering across disparate systems (e.g., labs, scheduling, ordering, spreadsheets), and providing a unified, up-to-date view of each patient's treatment journey. Oregon Health & Science University will be an early adopter. 'Every day counts when it comes to cancer care. The latest theranostics solutions will help our care teams more quickly and easily keep tabs on patient readiness and reduce patient coordination time—freeing up more time for clinicians to focus on direct patient care,' says Erik Mittra, M.D., Ph.D., professor of diagnostic radiology in the at Oregon Health & Science University. Altogether, GE HealthCare has the unique ability to provide solutions along every step of the theranostics care pathway. Our integrated portfolio of solutions provides clinicians with the isotopes, imaging, informatics, and molecular imaging agents necessary for the practice and advancement of precision care. For more information on GE HealthCare's innovative portfolio of theranostics-enabling solutions, please visit SNMMI show attendees are also encouraged stop by the company's booth (#638 and #1023) at New Orleans Ernest N. Morial Convention Center in New Orleans, Louisiana from June 21-24. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. i LesionID Pro with automated zero-click pre-processing is 510(k)-pending with the U.S. FDA. Not CE Marked and not licensed in accordance with Canadian law. Not available for sale in the United States, Europe, Canada, or any other region. ii Cancer. World Health Organization. Published February 3, 2022. Accessed March 2, 2023. iii Technology in development that represents ongoing research and development efforts. These technologies are not products and may never become products. Not CE marked. iv Omni Legend 21cm as compared to Discovery MI Gen1 20cm. As demonstrated in phantom testing. v Based on orders data of GE HealthCare PET/CT systems since 2010. vi Compared to NM/CT 870 DR. vii As compared to NM/CT 870 DR with Optima 540 CT. viii a ASiR-V reduces dose by 50% to 82% relative to FBP at the same image quality (Image quality as defined by low contrast detectability). viii b In clinical practice, the use of ASiR‐V may reduce CT patient dose depending on the clinical task, patient size, anatomical location, and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task. Low Contrast Detectability (LCD), Image Noise, Spatial Resolution and Artifact were assessed using reference factory protocols comparing ASiR‐V and FBP. The LCD was measured using 0.625 mm slices and tested for both head and body modes using the MITA CT IQ Phantom (CCT183, The Phantom Laboratory), using a model observer method.

Business Wire

a day ago

• Business Wire

EMEREN GROUP INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Emeren Group Ltd.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Emeren Group Ltd. (NYSE: SOL) to Shurya Vitra Ltd. Under the terms of the proposed transaction, shareholders of Emeren Group will receive $0.20 in cash per ordinary share or $2.00 in cash per American Depositary Share. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit